Send
Print
Soon Sumia Louam
Hengrui Pharma sold 224.5 million shares for HK$44.05 ($5.6) each. The total amount raised from the offering was HK$9.9bn ($1.3bn). According to the agreement, Hengrui will refrain from taking the option to expand the size of the offering.
The price offered by Hengrui signifies a discount of approximately 27.5% from the closing price on the Shanghai Stock Exchange on May 21.
This placement in Hong Kong follows closely behind Contemporary Amperex Technology's (CATL) offer, which was the largest in the world by volume since early 2025. The Chinese electric vehicle battery manufacturer initially secured $4.6bn, with the total climbing to $5.2bn due to the exercise of options.
Hengrui focuses on research in oncology and cardiovascular fields. Investment banks like Morgan Stanley, Citigroup, and Huatai Securities took part in its offering in Hong Kong.
source: bloomberg.com
The price offered by Hengrui signifies a discount of approximately 27.5% from the closing price on the Shanghai Stock Exchange on May 21.
This placement in Hong Kong follows closely behind Contemporary Amperex Technology's (CATL) offer, which was the largest in the world by volume since early 2025. The Chinese electric vehicle battery manufacturer initially secured $4.6bn, with the total climbing to $5.2bn due to the exercise of options.
Hengrui focuses on research in oncology and cardiovascular fields. Investment banks like Morgan Stanley, Citigroup, and Huatai Securities took part in its offering in Hong Kong.
source: bloomberg.com
